Garetosmab

Garetosmab is a fully human, experimental monoclonal antibody against activin-A. It has been tried in patients with fibrodysplasia ossificans progressiva and the manufacturer, Regeneron, also plans to test it in patients with obesity as an add-on to existing weight loss drugs such as GLP-1 agonists, in order to help patients maintain muscle mass during weight loss.